STAT+: Regeneron’s George Yancopoulos talks CRISPR, obesity drugs, and the next generation of Covid antibody cocktails

The discovery of a rare genetic mutation that seems to protect certain people from becoming obese may one day lead to drugs that can help people lose weight or prevent other complications like diabetes and heart disease, said Regeneron Pharmaceuticals co-founder and Chief Scientific Officer George Yancopoulos. Regeneron scientists and other collaborators published new findings about this protective mutation in the journal Science.

Yancopoulos sat down with the hosts of “The Readout LOUD” to discuss Regeneron’s genetic research efforts, which include partnering with Intellia Therapeutics on the first in vivo CRISPR treatment for a rare nerve disease.

Continue to STAT+ to read the full story…